Navigation Links
Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 Fourth Quarter and Full Year Financial Results
Date:2/23/2010

s.  The Phase 2 clinical trial is designed as a 12-week, randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX2931 and its effects on symptoms associated with rheumatoid arthritis. With enrollment in the study proceeding ahead of schedule, the Company has filed for regulatory authorization to permit enrollment of up to 200 patients, an increase from the originally-planned enrollment of up to 120 patients, which will increase the likelihood of observing a positive statistical trend. The study is being conducted at multiple centers in the United States and Eastern Europe.  Top-line data from the expanded trial are expected to be available around the end of the year.
  • Lexicon continues to enroll patients in a Phase 2a study of its drug candidate for carcinoid syndrome, LX1032, an inhibitor of tryptophan hydroxylase that reduces peripheral serotonin production without affecting brain serotonin levels.  The Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled study to evaluate the safety and tolerability of LX1032 and its effects on symptoms associated with carcinoid syndrome.  The study is expected to include up to 28 patients with carcinoid syndrome who are symptomatic despite treatment with currently available therapy.  Top-line data from the trial are expected to be available in the secon
    '/>"/>

  • SOURCE Lexicon Pharmaceuticals, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

    Related biology technology :

    1. Lexicon Announces Proposed Offering of 27,500,000 Shares of Common Stock
    2. Lexicon Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    3. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28, 2009
    4. Lexicon Initiates Phase 2 Clinical Trial of LX1032 in Patients With Carcinoid Syndrome
    5. Lexicon Names Ajay Bansal Executive Vice President and Chief Financial Officer
    6. Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week
    7. Lexicon to Provide Clinical Pipeline Update and Report First Quarter 2009 Financial Results on April 28, 2009
    8. Lexicon Pharmaceuticals 2008 Annual Report to Stockholders Available Online
    9. Nuevolution Announces Drug Discovery Alliance With Lexicon Pharmaceuticals
    10. Lexicon to Report Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
    11. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/10/2014)... may help in the fight against terrorism with the ... of explosives with the use of light and special ... and Actuators B: Chemical , the researchers describe a ... concentrations as low as 6.3 ppm (parts per million). ... minutes. , "Traditionally explosives detection has involved looking for ...
    (Date:7/10/2014)... PNAS (Proceedings of the National Academy of Sciences) ... deprivation have a significant effect on our metabolism. The ... time of day to test for diseases such as ... , Researchers from the University of Surrey and The ... sleep deprivation, body clock disruption and metabolism, and discovered ...
    (Date:7/10/2014)... observed the fractional quantum Hall effect in bilayer graphene ... be tuned by an electric field. , The ... confined to thin sheets are exposed to large magnetic ... thousands of individual electrons behave as a single system. ... well established, many details of this collective behavior remain ...
    (Date:7/10/2014)... forever. Nanophysics makes sure of that. Mechanics researchers at Linkping ... Physical Review E . Knowledge that can be of ... be able to sit still forever, and walk around upside ... soon be able to buy smart new fasteners that hold ... is, sooner or later the grip is lost, no matter ...
    Breaking Biology Technology:Detecting trace amounts of explosives with light 2Time of day crucial to accurately test for diseases, new research finds 2Columbia researchers observe tunable quantum behavior in bilayer graphene 2Columbia researchers observe tunable quantum behavior in bilayer graphene 3Even geckos can lose their grip 2
    ... 2011 Vermillion, Inc. (NASDAQ: VRML ), a ... call to give a company update following issuance of the ... Conference Call Information To access ... United States and Canada or +1 303 223-2683 internationally.  The ...
    ... Calif., April 19, 2011 Life Technologies ... will present at Baird,s 2011 Growth Stock Conference on ... Technologies, Chairman and Chief Executive Officer, will present on ... presentation, which will be available for three weeks following ...
    ... Today, H. Shep Wild, President and Chief Executive ... company focused on the research and development of ... a company overview to venture capital, pharmaceutical and ... Showcase 2011 hosted by the University of Florida ...
    Cached Biology Technology:Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 2Vermillion to Host Conference Call to Present Company Update and Review Financial Results for the First Quarter 2011 3Life Technologies to Present at Baird's 2011 Growth Stock Conference 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 2CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 3CureFAKtor Pharmaceuticals Featured at University of Florida Innovation Showcase 2011 4
    (Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
    (Date:7/10/2014)... 2014  Pomerantz LLP has filed a class ... the "Company")(NYSE-MKT: PVCT) and certain of its officers.  ... Court, Middle District of Tennessee ... class consisting of all persons or entities who ... 17, 2013 and May 22, 2014, both dates ...
    (Date:7/10/2014)... -- Unisys Corporation,s (NYSE: UIS ) subsidiary in ... that it has been selected by the Dutch Custodial Institutions ... Provision Biometrics solution for penitentiaries across The Netherlands ... a solution based on its open standards-based LEIDA ... is up to seven years, with the new system expected ...
    Breaking Biology News(10 mins):Blame it on the astrocytes 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 2SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Provectus Biopharmaceuticals, Inc. and Certain Officers - PVCT 3Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 2Unisys Delivers New Basic Provision Biometrics Solution to Dutch Custodial Institutions Service 3
    ... as a means to increase vegetation and preserve aesthetics ... cities, local character and biodiversity, researchers are looking to ... environments that are necessary in lightweight green roof design. ... survive in environments with little water--fit well in green ...
    ... fresh produce increases, vegetable and fruit producers are ... being challenged to examine traditional production practices in ... impact. A recent focus on both the positive ... across the globe working to find methods that ...
    ... 31 January 2014 VIB and CD3 (KU Leuven) ... agreement with AstraZeneca for the development of novel MALT1 ... The research teams of Thijs Baens and Peter ... Beyaert (VIB-UGent, Inflammation Research Center) were among the first ...
    Cached Biology News:Three native aromatics indicated for use in Mediterranean extensive green roofs 2Nitrogen management studied in greenhouse pepper production 2VIB&CD3 enter into license and collaboration agreement with AstraZeneca for development of MALT1 inhibitor 2
    Mouse monoclonal [PRMT5-21] to PRMT5 ( Abpromise for all tested applications). entrezGeneID: 10419 SwissProtID: O14744...
    Mouse TrkC Affinity Purified Polyclonal Ab...
    Mouse MMP-24 (MT5-MMP) MAb (Clone 143908)...
    TMB Slow Kinetic One Component HRP Microwell Substrate, 1 L...
    Biology Products: